Back to news

iSpecimen Reports 129% Year-Over-Year Increase in Third Quarter Revenue; Highlights Completed Orders for Federal Government and the Centers for Disease Control and Prevention (CDC)

Newsfile Corp•19/11/2026•16:05 ET
0

Key Highlights

  • ➤Q3 revenue approximately $244,000, up 129% year over year
  • ➤Specimens delivered rose 169% to 752 from 280
  • ➤Gross profit reached approximately $153,000 versus a $98,000 gross loss
  • ➤Net loss narrowed to approximately $2.2 million from $2.8 million
  • ➤iSpecimen fulfilled 21 biospecimen orders for nine government-affiliated organizations since 2020

Expert Statements

Shahin Behroyan, Chief Executive Officer of iSpecimen

“Our third quarter results reflect renewed momentum in customer demand, with revenue more than doubling and specimen volume up 169% from a year ago.”

Shahin Behroyan, Chief Executive Officer of iSpecimen

“Our work with the CDC and other government and public-sector organizations shows what our marketplace was built to do: give researchers access to hard-to-source specimens through a network of collection partners that would be difficult to assemble on their own.”

Shahin Behroyan, Chief Executive Officer of iSpecimen

“At the same time, we are fulfilling orders far more efficiently, with a significantly lower cost per specimen, and we see continued opportunity to support government-funded research as we move into 2027.”

Company has fulfilled 21 biospecimen orders for federal, state, and government-affiliated research organizations since 2020

Woburn, Massachusetts--(Newsfile Corp. - November 19, 2026) - iSpecimen Inc. (NASDAQ: ISPC), a global marketplace connecting researchers with biospecimens and clinical data, today reported a 129% year-over-year increase in third quarter 2026 revenue and highlighted its experience supporting government and public-sector research through the sourcing and fulfillment of human biospecimens.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in